Assessment of the contribution that direct allorecognition makes to the progression of chronic cardiac transplant rejection in humans

Circulation

Volumn 97, Issue 13, 1998, Pages 1257-1263

  Hornick, Philip I ^a   Mason, Philip D ^a   Yacoub, Magdi H ^b   Rose, Marlene L ^b   Batchelor, Richard ^a   Lechler, Robert I ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

Immune system; Immunology; Lymphocytes; Rejection; Transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN;

ALLOTRANSPLANTATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; HELPER CELL; HLA TYPING; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0032492761     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.13.1257     Document Type: Article

References (55)

1. Bieber C, Stinson E, Shumway N, Payne R, Kosek J. Cardiac transplantation in man. VII: cardiac allograft pathology. Circulation. 1970;41:753-779.
2. Billingham M. Cardiac transplant atherosclerosis. Transplant Proc. 1987;19(suppl 5):19-25.
3. Gao S, Schroeder J, Alderman E, Hunt SA, Valantine HA, Wiederhold V, Stinson EB. Prevalence of accelerated coronary artery disease in heart transplant survivors: comparison of cyclosporine and azathioprine regimens. Circulation. 1989;80(suppl III):III-100-III-5.
4. Uretsky B, Murali S, Reddy P, Rabin B, Lee A, Bartley P, Griffith B, Hardesty R, Trento A, Bahnson H. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisolone. Circulation. 1987;76:827-833.
5. Gao A, Alderman E, Schroeder J, Silverman J, Hunt S. Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. J Am Coll Cardiol. 1988;12:334-240.
6. Hess J, Hastillo A, Mohanakumar T, Cowley MJ, Vetrovac G, Szentpeterey S, Wolfgang TC, Lower RR. Accelerated atherosclerosis in cardiac transplantation: role of cytotoxic B-cell antibodies and hyperlipidemia. Circulation. 1983;68(suppl II):II-94-II-101.
7. Zerbe T, Uretsky B, Kormos R, Armitage J, Wolyn T, Griffith B, Hardesty R, Duquesnoy R. Graft atherosclerosis: effects of cellular rejection and human lymphocyte antigen. J Heart Lung Transplant. 1992;11:S104-S110.
8. Hosenpud J, Shipley J, Wagner C. Cardiac allograft vasculopathy: current concepts, recent developments and future directions. J Heart Lung Transplant. 1992;11:9-23.
9. Costanzo-Nordin M. Cardiac allograft vasculopathy: relationship with acute cellular rejection and histocompatibility. J Heart Lung Transplant. 1992;11:S90-S103.
10. Cramer D, Chapman F, Wu G, Harnaha J, Quian S, Makowka L. Cardiac transplantation in the rat. II: alteration of the severity of donor graft arteriosclerosis by modulalion of the host immune response. Transplantation. 1990;50:554-558.
11. Shin Y, Adams D, Wyner L, Akalin E, Sayegh M, Karnovsky M. Intrathymic tolerance in the Lewis-to-F344 chronic cardiac allograft rejection model. Transplantation. 1995;59:1647-1653.
12. Shi C, Lee W, HE Q, Zhang D, Fletcher DL, Newell JB Haber E. Immunologic basis of transplant-associated arteriosclerosis. Proc Natl Acad Sci U S A. 1996;93:4051-4056.
13. Dunn M, Crisp S, Rose M, Taylor P, Yacoub M. Anti-endothelial antibodies and coronary artery disease after cardiac transplantation. Lancet. 1992;339:1566-1570.
14. Crisp S, Dunn M, Rose M, Taylor P, Yacoub M. Antiendothelial antibodies after heart transplantation: the accelerating factor in transplant associated coronary artery disease. J Heart Lung Transplant. 1994;13:81-92.
15. Suciu-Foca N, Reed E, Marboe C, Harris P, Yu PX, Suu YK, Ho E, Rose E, Reernstmak K, King DW. The role of anti-HLA antibodies in heart transplantation. Transplantation. 1991;51:716-724.
16. Reed E, Hong B, Ho E, Harris P, Weinberger J, Suciu-Foca N. Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant-associated coronary artery disease. Transplantation. 1996;61:566-572.
17. Billingham M. Graft coronary disease: old and new dimensions. Cardiovasc Pathol. 1997;6:95-101.
18. Gao S, Schroeder J, Alderman EL, Hunt SA, Silverman JF, Wiederhold V, Stinson EB. Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient. Circulation. 1987;76:56-61.
19. Barbír M, Kushwaha S, Hunt B, Macken A, Thompson GR, Mitchell A, Robinson D, Yacoub M. Lipoprotein(a) and accelerated coronary artery disease in cardiac transplant patients. Lancet. 1992;340:1500-1502.
20. Bradley J, Mowat AM, Bolton E. Processed MHC class I alloantigen as the stimulus for CD4+ T-cell dependent antibody-mediated graft rejection. Immunol Today. 1992;13:434-438.
21. Shokes D, Wood K. Indirect presentation of MHC antigens in transplantation. Immunol Today. 1994;15:32-38.
22. Auchinloss HJ, Sutan H. Antigen processing and presentation in transplantation. Curr Opin Immunol. 1996;8:681-687.
23. Lechler R, Lombardi G, Batchelor J, Reinsmoen N, Bach F. The molecular basis of alloreactivity. Immunol Today. 1990;11:83-88.
24. Lechler RI, Heaton T, Barber L, Ball V, Batchelor J, Lombardi G. Molecular mimicry by major histocompatibility complex molecules and peptides accounts for some alloresponses. Immunol Lett. 1992;34:63-70.
25. Schwarer A, Jiang Y, Deacock S, Brookes PA, Barrett AJ, Goldman JM, Batchelor JR, Lechler RI. Comparison of helper and cytotoxic antirecipient T cell frequencies in unrelated bone marrow transplantation. Transplantation. 1994;58:1198-1203.
26. Kaminski E, Hows J, Man S, Brookes P, Mackinnon S, Hughes T, Avakian O, Goldman JM, Batchelor JR. Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. Transplantation. 1989;48:608-613.
27. Lechler R, Batchelor J. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J Exp Med. 1982;155:31-41.
28. Lechler R, Batchelor J. Immunogenicity of retransplanted rat kidney allografts. J Exp Med. 1982;156:1835-1841.
29. Batchelor J, Welsh K, Maynard A, Burgos H. Failure of long surviving passively enhanced kidney allografts to provoke T-dependent alloimmunity. J Exp Med. 1979;150:455-464.
30. Braun M, McCormack A, Webb G, Batchelor J. Mediation of acute but not chronic rejection of the MHC incompatible rat kidney grafts by alloreactive CD4 T cells activated by the direct pathway of sensitisation. Transplantation. 1993;55:177-182.
31. Braun M, McCormack A, Webb G, Batchelor J. Evidence for clonal anergy as a mechanism responsible for the transplantation tolerance. Eur J Immunol 1993;23:1462-1468.
32. Fangmann J, Dalchau R, Fahre J. Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides. J Exp Med. 1992;175:1521-1529.
33. Auchinloss HJ, Lee R, Shea S, Markowitz J, Grusby M, Glimcher L. The role of 'indirect' recognition in initiating rejection of skin grafts from major histocompatibility complex class II-deficient mice. Proc Natl Acad Sci U S A. 1993;90:3373-3377.
34. Liu Z, Coloval A, Tugulea S, Reed EF, Fisher PE, Mancini D, Rose EA, Cortesini R, Michler RE, Suciu-Foca N. Indirect recognition of donor HLA-DR peptides in organ allograft rejection. J Clin Invest. 1996;98:1150-1157.
35. Brand D, Ray J, Hare D, Kayhoe D, McClelland J. Preliminary trials towards standardisation of leucocyte typing. In: Terasaki P, ed. Histocompatibility Tenting. Copenhagen, Denmark: Munksgaard; 1970:357-367.
36. Van Rood J, Van Leeuwen A, Ploem J. Simultaneous detection of two cell populations by two-color fluorescence and application to the recognition of B-cell determinants. Nature. 1976;262:795-797.
37. Buyse I, Decorte R, Baens M, Cuppens H, Semane G, Emonds MP, Marynen P, Cassiman JJ. Rapid DNA typing of Class II HLA antigens using the polymerase chain reaction and reverse dot blot hybridization. Tissue Antigens. 1993;41:1-14.
38. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens. 1992;39:225-235.
39. Deacock S, Schwarer A, Batchelor R, Goldman J, Lechler R. A rapid limiting dilution assay for measuring the frequencies of alloreactive, interleukin-2 producing T cells in humans. J Immunol Methods. 1992;147:83-92.
40. Kaminski E, Sharrock C, Hows J, Ritter M, Arthur C, Mackinnon S, Batchelor JR. Frequency analysis of cytotoxic T lymphocyte precursorspossible relevance to HLA-matched unrelated donor bone marrow transplantation. Bone Marrow Transplant. 1988;3:149-155.
41. Hornick PI, Brookes PA, Mason PD, Taylor KM, Yacoub MH, Rose ML, Batchelor R, Lechler RI. Optimizing a limiting dilution culture system for quantifying the frequency of IL-2 producing alloreactive helper T lymphocytes. Transplantation. 1997;64:472-479.
42. Gillis S, Smith K. Long term culture of tumor-specific cytotoxic T cells. Nature. 1977;268:154-156.
43. Mosmann T, Yokata T, Kastelein R, Zurawski S, Arai N, Takebe Y. Species specificity of T cell stimulating activities of IL-2 and BSF (IL-4). J Immunol. 1987;138:1813-1816.
44. Clouse K, Bach F, Orosz C. Detection of HSV-1-induced lymphokine production in human cells by a direct indicator cell addition assay. J Immunol. 1984;132:2961-2967.
45. Finney D. Statistical Method in Biological Assay. London, UK: Charles Griffin; 1978.
46. Zanker B, Joos-Rudiger J, Franz H, Wagner H, Kabelitz D. Evidence that functional deletion of donor-reactive T lymphocytes in kidney allograft recipients can occur at the level of cytotoxic T cells, IL-2-producing cells or both. Transplantation. 1993;56:628-632.
47. Reinsmoen N, Jackson A, McSherry C, Ninova D, Wiesner RH, Kondo M, Krom RAF, Hertz MI, Bolman M, Matas AJ. Organ-specific patterns of donor antigen-specific hyporeactivity and peripheral blood allogeneic microchimerism in lung, kidney, and liver transplant recipients. Transplantation. 1995;60:1546-1554.
48. DeBruyne L, Renlund D, Bishop D. Evidence that human cardiac allograft acceptance is associated with a decrease in donor-reactive helper T lymphocytes. Transplantation. 1995;59:778-783.
49. Mason P, Robinson C, Lechler R. Detection of donor-specific hyporesponsiveness following late failure of human renal allografts. Kidney Int. 1996;50:1019-1025.
50. Lafferty K, Cunningham A. A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci. 1975;53:27-42.
51. Boussiotis V, Freeman G, Gray G, Gribben J, Nadler L. B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med. 1993;178:1753-1763.
52. Linsley P, Brady W, Grosmaire L, Aruffo A, Damle N, Ledbetter J. Binding of the B cell activation antigen B7 to CD28 co-stimulates T cell proliferation and interieukin-2 mRNA accumulation. J Exp Med. 1991;173:721-730.
53. June C, Bluestone J, Nadler L, Thompson C. The B7 and CD28 receptor families. Immunol Today. 1994;15:321-331.
54. Jenkins M, Schwartz R. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med. 1987;165:302-319.
55. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med. 1986;314:488-500.